Clinical Trials Logo
  1. Home
  2. Thoracic Neoplasms
  3. NCT03306693

Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers — EmoVie_K  

Digestive System Neoplasms Clinical Trial

Official title:
Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers as Compared to Standard Management

Clinical Trial Summary

The aim of this study is to test whether a short educational intervention about emotional skills can improve survivor cancer patient emotional skills and quality of life. Half of participants will follow the educational intervention about emotional skills, while the other half will practice relaxation followed by a non-directive talking group. The educational intervention should give better results on patient emotional skills and quality of life than the control group.

Clinical Trial Description

After the end of treatments, cancer patients face a difficult time because it is expected that they return to normal, but at the same time they still have to struggle with the aftermath of cancer and fear of recurrence. This is why there is room in this period for an intervention designed to help patients to cope with their emotions. . Patient emotional skills are patient abilities to identify, express and manage their emotions for the best possible psychological adjustment. In general population, emotional skills have been shown to be highly related to a better quality of life. In this randomized controlled study, bronchopulmonary and oesogastric cancer patients between 6 months and 2 years after the end of treatments will undergo either the emotional skills intervention (intervention group) or the relaxation group (control group). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03306693
Study type Interventional
Source University Hospital, Lille
Contact
Status Terminated
Phase N/A
Start date October 26, 2017
Completion date May 7, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06026800 - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms Phase 1
Recruiting NCT06019702 - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms Phase 1
Recruiting NCT06026774 - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms Phase 1
Completed NCT02909452 - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Recruiting NCT04518852 - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC Phase 2
Completed NCT03717298 - Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma Phase 2
Recruiting NCT05322486 - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Recruiting NCT04556344 - Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer N/A
Active, not recruiting NCT01037049 - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks Phase 2
Recruiting NCT02208804 - Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization Phase 2/Phase 3
Completed NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients Phase 2
Recruiting NCT03303495 - A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC Phase 3
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Recruiting NCT03271255 - Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) Phase 2
Recruiting NCT03221335 - EUS-guided RFA for Solid Abdominal Neoplasms N/A
Recruiting NCT02487017 - DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT01556815 - Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma Phase 2
Recruiting NCT04949282 - Spanish Series of Patients Treated With the Radionuclide Lutetium177
Completed NCT01964430 - Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Phase 3